Niagen Bioscience Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
$NAGE
Medicinal Chemicals and Botanical Products
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The Nasdaq Capital Market | ||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07 Submission of Matters to a Vote of Security Holders.
Set forth below are the results of the matters submitted for a vote of stockholders at the Company’s 2026 Annual Meeting.
Proposal 1 — Election of directors.
The following directors were elected to serve until the Company’s 2027 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director’s death, resignation or removal.
| Director Elected | For | Withheld | Broker Non-Votes | |||||||||||||||||
| Frank L. Jaksch, Jr. | 44,531,507 | 759,870 | 13,274,979 | |||||||||||||||||
| Robert Fried | 44,822,825 | 468,552 | 13,274,979 | |||||||||||||||||
| Steven Rubin | 28,495,147 | 16,796,230 | 13,274,979 | |||||||||||||||||
| Wendy Yu | 44,520,972 | 770,405 | 13,274,979 | |||||||||||||||||
| Gary Ng | 44,446,052 | 845,325 | 13,274,979 | |||||||||||||||||
| Kristin Patrick | 43,608,014 | 1,683,363 | 13,274,979 | |||||||||||||||||
| Ann Cohen | 44,360,218 | 931,159 | 13,274,979 | |||||||||||||||||
| Hamed Shahbazi | 30,544,086 | 14,747,291 | 13,274,979 | |||||||||||||||||
Proposal 2 — Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 56,152,066 | 2,256,090 | 158,200 | — | |||||||||||||||||
* No broker non-votes arose in connection with Proposal 2.
Proposal 3 — Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers.
| For | Against | Abstain | Broker Non-Votes | |||||||||||||||||
| 43,188,958 | 1,930,441 | 171,978 | 13,274,979 | |||||||||||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| NIAGEN BIOSCIENCE, INC. | ||||||||
| Dated: June 29, 2026 | By: | /s/ Ozan Pamir | ||||||
| Name: Ozan Pamir | ||||||||
| Chief Financial Officer | ||||||||